三生国健药业（上海）股份有限公司2025年年度业绩快报公告

Financial Performance Summary - In 2025, the company achieved operating revenue of 419,911.84 million RMB, representing an increase of 251.81% compared to the previous year [4] - The net profit attributable to the parent company was 293,871.44 million RMB, with a growth rate of 317.09% year-on-year [4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 280,533.07 million RMB, showing an increase of 1,041.01% [4] Financial Position - As of the end of the reporting period, the total assets of the company amounted to 888,736.14 million RMB, reflecting a growth of 48.99% from the beginning of the year [4] - The equity attributable to the parent company reached 845,671.37 million RMB, which is an increase of 51.89% compared to the beginning of the year [4] Significant Changes in Financial Metrics - Key financial metrics such as total operating revenue, operating profit, total profit, net profit attributable to the parent company, and basic earnings per share all experienced significant growth, primarily due to a major collaboration with Pfizer Inc. [5] - The company recognized revenue of approximately 2.89 billion RMB from the upfront payment received from Pfizer for the 707 project [5]